L
Laurent Mineur
Researcher at University of Paris
Publications - 134
Citations - 13107
Laurent Mineur is an academic researcher from University of Paris. The author has contributed to research in topics: Colorectal cancer & Oxaliplatin. The author has an hindex of 36, co-authored 120 publications receiving 11359 citations.
Papers
More filters
Journal ArticleDOI
Chemotherapy with preoperative radiotherapy in rectal cancer
Jean-François Bosset,Laurence Collette,Gilles Calais,Laurent Mineur,Philippe Maingon,L. Radosevic-Jelic,Alain Daban,Etienne Bardet,Alexander Beny,Jean-Claude Ollier +9 more
TL;DR: In patients with rectal cancer who receive preoperative radiotherapy, adding fluorouracil-based chemotherapy preoperatively or postoperatively has no significant effect on survival.
Journal ArticleDOI
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey,Eric Van Cutsem,Alberto Sobrero,Salvatore Siena,Alfredo Falcone,Marc Ychou,Yves Humblet,Olivier Bouché,Laurent Mineur,Carlo Barone,Antoine Adenis,Josep Tabernero,Takayuki Yoshino,Heinz-Josef Lenz,Richard M. Goldberg,Daniel J. Sargent,Frank Cihon,Lisa Cupit,Andrea Wagner,D. Laurent +19 more
TL;DR: Evidence is provided for a continuing role of targeted treatment after disease progression, with regorafenib offering a potential new line of therapy in this treatment-refractory population of patients with metastatic colorectal cancer.
Journal ArticleDOI
OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study
Christophe Tournigand,Andrés Cervantes,Arie Figer,Gérard Lledo,M. Flesch,Marc Buyse,Laurent Mineur,Elisabeth Carola,Pierre-Luc Etienne,Fernando Rivera,Isabel Chirivella,N. Perez-Staub,Christophe Louvet,Thierry André,Isabelle Tabah-Fisch,Aimery de Gramont +15 more
TL;DR: Oxaliplatin can be safely stopped after six cycles in a FOLFOX regimen, and further study is needed to fully evaluate oxali Platin reintroduction.
Journal ArticleDOI
Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib the LAP07 randomized clinical trial
Pascal Hammel,Florence Huguet,Jean-Luc Van Laethem,David Goldstein,Bengt Glimelius,Pascal Artru,Ivan Borbath,Olivier Bouché,Jenny Shannon,Jenny Shannon,Thierry André,Laurent Mineur,Benoist Chibaudel,Franck Bonnetain,Christophe Louvet +14 more
TL;DR: In this open-label, randomized trial involving patients with locally advanced pancreatic cancer with disease controlled after 4 months of induction chemotherapy, there was no significant difference in overall survival with chemoradiotherapy compared with chemotherapy alone and there wasno significant difference with gem citabine compared with gemcitabine plus erlotinib used as maintenance therapy.
Journal ArticleDOI
Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2
Jean-Pierre Gerard,David Azria,Sophie Gourgou-Bourgade,Isabelle Martel-Laffay,Christophe Hennequin,Pierre-Luc Etienne,Véronique Vendrely,Eric Francois,Olivier Bouché,Xavier Mirabel,Bernard Denis,Laurent Mineur,J. F. Berdah,Marc Mahé,Yves Becouarn,Olivier Dupuis,Gérard Lledo,C. Montoto-Grillot,Thierry Conroy +18 more
TL;DR: The benefit of oxaliplatin was not demonstrated and this drug should not be used with concurrent irradiation, and Cap 50 merits investigation for T3-4 rectal cancers.